US equities
|
NVDA
$239.77
▲+2.49%
SPCX
$169.35
▲+6.54%
MU
$1,063.06
▼-1.10%
TSLA
$379.82
▲+2.49%
SNDK
$1,704.11
▼-0.92%
MSFT
$528.04
▲+2.03%
INTC
$116.03
▼-2.77%
META
$742.82
▲+2.02%
NVDA
$239.77
▲+2.49%
SPCX
$169.35
▲+6.54%
MU
$1,063.06
▼-1.10%
TSLA
$379.82
▲+2.49%
SNDK
$1,704.11
▼-0.92%
MSFT
$528.04
▲+2.03%
INTC
$116.03
▼-2.77%
META
$742.82
▲+2.02%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Verve Therapeutics, Inc. - Common Stock
(NQ:
VERV
)
11.13
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verve Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 03, 2025
From
Verve Therapeutics
Via
GlobeNewswire
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
↗
December 20, 2024
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.
Via
Investor's Business Daily
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 29, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Analyst Scoreboard: 4 Ratings For Verve Therapeutics
↗
November 06, 2024
Via
Benzinga
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
November 05, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
October 27, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV
October 26, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and iLearningEngines and Encourages Investors to Contact the Firm
October 21, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
October 21, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and iLearningEngines and Encourages Investors to Contact the Firm
October 15, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
October 14, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
October 11, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and Ardelyx and Encourages Investors to Contact the Firm
October 08, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm – VERV
October 08, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
October 07, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and Ardelyx and Encourages Investors to Contact the Firm
October 04, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
VERV REMINDER – Robbins LLP Urges VERV Investors to Obtain Legal Counsel in Light of the Pending Lead Plaintiff Deadline
October 04, 2024
From
Robbins LLP
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
October 02, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and Ardelyx and Encourages Investors to Contact the Firm
September 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
September 30, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, Domino’s, and Ardelyx and Encourages Investors to Contact the Firm
September 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
September 25, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline
September 23, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
September 21, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
September 19, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
September 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit
September 17, 2024
From
Robbins LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
